Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

- In Patients With BPH, Clinical Benefit After Ozarelix Was Maintained For

Up To Six Months - Pivotal Trials Expected To Commence Before Year End Or Soon Thereafter

IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today presented updated Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the 29th Congress of the Societe Internationale d'Urologie in Paris, France.

"The results of this Phase 2 study demonstrate that the effects of a single dosing regimen consisting of two injections on day one and fifteen are maintained for up to six months, which is superior to what is usually seen with currently approved drugs for BPH," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "A second 78-patient U.S. Phase 2b study, in which duration of follow-up is 9 months, completed enrollment in May. We look to the Phase 2b data to verify and expand on the experience from the Phase 2 study presented today. We continue to believe that ozarelix could help serve the large unmet medical need for more effective BPH treatments."

The efficacy and safety of ozarelix, a GnRH antagonist, given intramuscularly (IM) was assessed in men with moderate to severe Lower Urinary Tract Symptoms (LUTS) due to BPH in a randomized, double-blind, placebo- controlled, multi-center, Phase 2 dose-ranging study.

Eligible patients entered a 4-week, single blind, placebo run-in to establish baseline IPSS and urine-flow values. Patients (N=144) meeting the inclusion criteria were randomly allocated and received an IM injec
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... data demonstrates that flibanserin, a novel, non-hormonal medicine being ... dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not impair ... when taken at bedtime. The data was presented at ... (SMSNA) 20th Annual Fall Scientific Meeting in ... accepted this study as a late breaking abstract for ...
(Date:11/22/2014)... Nov. 21, 2014 MEDITE Group acquired by CytoCore, ... and the 3 rd quarter sales ended September 30, ... $448,000 for the nine months ended September 2014 and a ... our 3 rd quarter is usually a seasonable weak ... July into September for many countries worldwide, we are proud ...
(Date:11/21/2014)... 21, 2014  The University of Maryland,s A. James ... groundbreaking of the new A. James Clark Hall at ... will cultivate transformative new engineering and biomedical technologies to ... at 10:00 a.m. on November 21 at the site ... Lot, adjacent to the Jeong H. Kim Engineering Building, ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... poultry ... processing plants., SHREVEPORT, La., Nov. ... poultry processing, was identified,in an October 2007 Watt Poultry USA article ... in large-scale processing plants, University of,Georgia Associate Professor of Poultry Science ...
... DEERFIELD, Ill., Nov. 6 In,recognition of her ... sexual behaviors among African-American, South-African and,Latino youth and ... Tau,International, announced the selection of Loretta Sweet Jemmott, ... 2007 Episteme Award. Jemmott was presented with ...
Cached Medicine Technology:FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved 2Honor Society of Nursing Recognizes Researcher of HIV Risk Prevention for Poor and Underserved 3
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/24/2014)... "My friend was killed when a vehicle ... street in his motorized wheelchair," said an inventor from ... up with this idea so that people in wheelchairs ... the Safety Lites to make a wheelchair highly visible, ... ensures that motorists can see the wheelchair. This helps ...
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic ... - Asia-Pacific” provides quantitative analysis of the three ... invasive body contouring devices, non-invasive body contouring devices ... size data by revenue and volume over the ... Japan, South Korea, Australia and India. It uses ...
(Date:11/23/2014)... friends have more influence on teens, alcohol use than ... "We,ve known for a long time that ... use, but there are no common studies that distinguished ... influence on those decisions," Jonathon Beckmeyer, an assistant professor ... a university news release. Beckmeyer analyzed data gathered ...
(Date:11/23/2014)... To show thanks to new and old customers, ... evening dresses for weddings. Customers who need custom outfits ... a distinguished dress manufacturer, and it is among the ones ... a very long time. The CEO of this company says, ... able to buy not only a beautiful dress, but also ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... -- Researchers from Duke University, the University of Cincinnati ... hoping to find a geographical pattern to help explain ... disease amyotrophic lateral sclerosis (ALS) at twice the normal ... layering military records of troop locations onto Gulf-area maps, ...
... in Progressive Inflammatory brain Disease) study at the Peninsula Medical ... news that the full cohort of 493 people with multiple ... is a clinical trial which will evaluate whether tetrahydrocannabinol (THC), ... plant (and the main active ingredient) is able to slow ...
... the only ones who need to be concerned about ... may trigger serious cardiovascular problems for some spectators. ... at Northwestern University,s Feinberg School of Medicine warn that ... of pollution can cause heart attacks and strokes within ...
... N.H., July 21 iCAD, Inc. (Nasdaq:,ICAD), an ... the completion of its previously announced,agreement to purchase ... technology company based in White Plains, NY. The,purchase ... in cash and,1,086,957 shares of iCAD common stock. ...
... Experienced a 15 Percent Increase in Prescription ... Report from HealthLeaders-InterStudy, NASHVILLE, Tenn., July ... care market intelligence, reports that Excellus,BlueCross BlueShield ... pharmacy programs and public education efforts. According ...
... Ala., July 21 Health,Care Systems, Inc. (HCS), ... market leader in medication reconciliation solutions, has entered,into ... the largest,locally owned not-for-profit hospitals in the nation ... as a teaching facility for The,University of Alabama ...
Cached Medicine News:Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 2Health News:Researchers probe geographical ties to ALS cases among 1991 Gulf War veterans 3Health News:Milestone for cannabinoid MS study 2Health News:Beijing pollution may trigger heart attacks, strokes 2Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2
Gently curved shaft with blunt angled tip is ideal for chopping the lens during anterior chamber phacoemulsification....
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
2.0 mm bulbous tip with 6 mm flat portion. Flat serrated handle with polished finish. Overall length: 5.4 inches. Most popular size or model....
Medicine Products: